NCT05357885View on ClinicalTrials.gov

Quantitative COVID-19 SARS-CoV-2 Antibody Pre and Post Cardiopulmonary Bypass

CompletedOBSERVATIONAL
Enrollment

60

Participants

Timeline

Start Date

November 17, 2021

Primary Completion Date

March 17, 2022

Study Completion Date

March 17, 2022

Conditions
Laboratory Assessment SARS-CoV-2 Antibody Levels Before and After Surgery for Patients Requiring Cardiopulmonary Bypass
Interventions
DIAGNOSTIC_TEST

SARS-CoV-2 Antibody test

SARS-CoV-2 antibody test at Jefferson is Roche Elecsys Anti-SARS-CoV-2 immunoassays performed under FDA's Emergency Use Authorization.

Trial Locations (1)

19107

Thomas Jefferson University, Philadelphia

All Listed Sponsors
lead

Thomas Jefferson University

OTHER

NCT05357885 - Quantitative COVID-19 SARS-CoV-2 Antibody Pre and Post Cardiopulmonary Bypass | Biotech Hunter | Biotech Hunter